Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: Relevance for disease evolution

Leukemia

Volumn 29, Issue 1, 2015, Pages 249-252

  Cabagnols, X ^a,b,c   Defour, J P ^d,e,f   Ugo, V ^g,h,i   Ianotto, J C ^g   Mossuz, P ^j   Mondet, J ^j   Girodon, F ^k,l   Alexandre, J H ^k   Mansier, O ^m   Viallard, J F ⁿ   Lippert, E ^m   Murati, A ^o   Mozziconacci, M J ^o   Saussoy, P ^f   Vekemans, M C ^f   Knoops, L ^e   Pasquier, F ^a,b,c   Ribrag, V ^a,b,c   Solary, E ^a,b,c   Plo, I ^a,b,c   Constantinescu, S N ^d,e   Casadevall, N ^a,b,p   Vainchenker, W ^a,b,c   Marzac, C ^p,q,r   Bluteau, O ^a,b,c   more..

^a INSERM   (France)

^b Universite Paris Sud   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^e DE DUVE INSTITUTE   (Belgium)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g BREST UNIVERSITY HOSPITAL   (France)

^h FACULTÉ DE MÉDECINE ET DES SCIENCES DE LA SANTÉ   (France)

ⁱ French Blood Agency   (France)

^j LABORATOIRE TIMC IMAG   (France)

^k DIJON UNIVERSITY HOSPITAL   (France)

^l Institut Médical de Génétique et d Immunologie   (France)

^m UNIVERSITÉ DE BORDEAUX   (France)

ⁿ HAUT LÉVÊQUE HOSPITAL   (France)

^o INSTITUT PAOLI CALMETTES   (France)

^p HÔPITAL SAINT ANTOINE   (France)

^q SORBONNE UNIVERSITÉ   (France)

^r CENTRE DE RECHERCHE SAINT ANTOINE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; CALRETICULIN; ISOPROTEIN;

ADULT; AGED; CALRETICULIN TYPE 1 GENE; CALRETICULIN TYPE 2 GENE; CARBOXY TERMINAL SEQUENCE; CHILD; DISEASE COURSE; EXON; FEMALE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEMOGLOBIN DETERMINATION; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; THROMBOCYTE COUNT; THROMBOCYTHEMIA; ADOLESCENT; GENETICS; MIDDLE AGED; MUTATION; MYELOID METAPLASIA; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CALRETICULIN; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; PRIMARY MYELOFIBROSIS; PROTEIN ISOFORMS; THROMBOCYTHEMIA, ESSENTIAL; YOUNG ADULT;

EID: 84920596808     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.270     Document Type: Letter

References (14)

1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390.
2. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-2405.
3. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112: 2190-2198.
4. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953.
5. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 2008; 112: 141-149.
6. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148.
7. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
8. Chi J, Nicolaou KA, Nicolaidou V. Calreticulin gene exon 9 frameshift mutations in patients with thrombocytosis. Leukemia 2013; 28: 1152-1154.
9. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; 123: 2220-2228.
10. Maffioli M, Genoni A, Caramazza D, Mora B, Bussini A, Merli M et al. Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia 2014; 28: 1357-1360.
11. Rumi E, Harutyunyan AS, Pietra D, Milosevic JD, Casetti IC, Bellini M et al. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood 2014; 123: 2416-2419.
12. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; 28: 1472-1477.
13. Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL et al. Type 1 vs type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol 2014; 89: E121-E124.
14. Rampal R, Al-Shahrour F, Abdel-Wahab O, Patel J, Brunel JP, Mermel CH et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 2014; 123: e123-e133.